The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Sep. 20, 2022

Filed:

Nov. 22, 2016
Applicant:

Five Prime Therapeutics, Inc., South San Francisco, CA (US);

Inventors:

Kristen Pierce, Burlingame, CA (US);

Janine Powers, Alameda, CA (US);

Servando Palencia, San Francisco, CA (US);

Robert Sikorski, Woodside, CA (US);

Majid Ghoddusi, South San Francisco, CA (US);

Kartik Krishnan, South San Francisco, CA (US);

Assignee:

Other;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07K 16/28 (2006.01); C07K 16/30 (2006.01); A61K 39/00 (2006.01); G01N 33/50 (2006.01); G01N 33/574 (2006.01);
U.S. Cl.
CPC ...
C07K 16/2863 (2013.01); C07K 16/2818 (2013.01); C07K 16/2896 (2013.01); C07K 16/303 (2013.01); C07K 16/3015 (2013.01); C07K 16/3023 (2013.01); C07K 16/3038 (2013.01); C07K 16/3046 (2013.01); C07K 16/3069 (2013.01); C07K 16/3084 (2013.01); G01N 33/5091 (2013.01); G01N 33/57407 (2013.01); G01N 33/57446 (2013.01); G01N 33/57492 (2013.01); A61K 2039/505 (2013.01); A61K 2039/507 (2013.01); A61K 2039/55 (2013.01); C07K 2317/34 (2013.01); C07K 2317/41 (2013.01); G01N 2333/71 (2013.01); G01N 2800/52 (2013.01);
Abstract

Provided herein are uses of fibroblast growth factor receptor 2 (FGFR2) inhibitors in cancer treatment, in some cases in combination with immune stimulating agents, such as inhibitors of PD-1 or PD-L1. In some embodiments, FGFR2 inhibitors may comprise FGFR2 antibodies or FGFR2 extracellular domain (ECD) polypeptides, or FGFR2 ECD fusion molecules comprising an FGFR2 ECD and a fusion partner. In some embodiments, PD-1/PD-L1 inhibitors may comprise anti-PD-1 antibodies such as antibodies that bind to PD-1 or to PD-L1 and inhibit interactions between these proteins, as well as PD-1 fusion proteins or polypeptides.


Find Patent Forward Citations

Loading…